Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect
Z Zhao, X Dai, C Li, X Wang, J Tian, Y Feng… - European journal of …, 2020 - Elsevier
The pyrazolone structural motif is a critical element of drugs aimed at different biological end-
points. Medicinal chemistry researches have synthesized drug-like pyrazolone candidates …
points. Medicinal chemistry researches have synthesized drug-like pyrazolone candidates …
A systematic review on anti-diabetic properties of chalcones
The use of anti-diabetic drugs has been increasing worldwide and the evolution of
therapeutics has been enormous. Still, the currently available anti-diabetic drugs do not …
therapeutics has been enormous. Still, the currently available anti-diabetic drugs do not …
Functional Characterization and Structural Basis of an Efficient Di-C-glycosyltransferase from Glycyrrhiza glabra
A highly efficient di-C-glycosyltransferase GgCGT was discovered from the medicinal plant
Glycyrrhiza glabra. GgCGT catalyzes a two-step di-C-glycosylation of flopropione-containing …
Glycyrrhiza glabra. GgCGT catalyzes a two-step di-C-glycosylation of flopropione-containing …
Exploring and applying the substrate promiscuity of a C-glycosyltransferase in the chemo-enzymatic synthesis of bioactive C-glycosides
K Xie, X Zhang, S Sui, F Ye, J Dai - Nature communications, 2020 - nature.com
Bioactive natural C-glycosides are rare and chemical C-glycosylation faces challenges
while enzymatic C-glycosylation catalyzed by C-glycosyltransferases provides an alternative …
while enzymatic C-glycosylation catalyzed by C-glycosyltransferases provides an alternative …
Natural products targeting mitochondria: emerging therapeutics for age-associated neurological disorders
Mitochondria are the primary source of energy production in the brain thereby supporting
most of its activity. However, mitochondria become inefficient and dysfunctional with age and …
most of its activity. However, mitochondria become inefficient and dysfunctional with age and …
Aspalathin from rooibos (Aspalathus linearis): a bioactive C-glucosyl dihydrochalcone with potential to target the metabolic syndrome
Aspalathin is a C-glucosyl dihydrochalcone that is abundantly present in Aspalathus
linearis. This endemic South African plant, belonging to the Cape Floristic region, is normally …
linearis. This endemic South African plant, belonging to the Cape Floristic region, is normally …
Dihydrochalcones: Methods of acquisition and pharmacological properties—A first systematic review
M Stompor, D Broda, A Bajek-Bil - Molecules, 2019 - mdpi.com
Dihydrochalcones are a class of secondary metabolites, for which demand in biological and
pharmacological applications is still growing. They posses several health-endorsing …
pharmacological applications is still growing. They posses several health-endorsing …
New insights into the efficacy of aspalathin and other related phytochemicals in type 2 diabetes—A review
CJF Muller, E Joubert, N Chellan, Y Miura… - International Journal of …, 2021 - mdpi.com
In the pursuit of bioactive phytochemicals as a therapeutic strategy to manage metabolic risk
factors for type 2 diabetes (T2D), aspalathin, C-glucosyl dihydrochalcone from rooibos …
factors for type 2 diabetes (T2D), aspalathin, C-glucosyl dihydrochalcone from rooibos …
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review
Gliflozins constitute an important class of compounds useful as sodium glucose co-
transporter (SGLT2) inhibitors to treat type-II diabetes. They act by blocking sodium-glucose …
transporter (SGLT2) inhibitors to treat type-II diabetes. They act by blocking sodium-glucose …
Glucosylpolyphenols as inhibitors of Aβ-induced Fyn kinase activation and tau phosphorylation: synthesis, membrane permeability, and exploratory target assessment …
AM De Matos, MT Blazquez-Sanchez… - Journal of medicinal …, 2020 - ACS Publications
Despite the rapidly increasing number of patients suffering from type 2 diabetes, Alzheimer's
disease, and diabetes-induced dementia, there are no disease-modifying therapies that are …
disease, and diabetes-induced dementia, there are no disease-modifying therapies that are …